NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study s ...

PALO ALTO, Calif., Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA. Glaucoma is the leading cause of irreversible blindnes ...

Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin's QRX003 product is on track to obtain the first regulatory approval for Netherton Syndrome. ASHBURN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has launched the "NETHERTON N ...

Inflection Point Fund and other related investors, including Chairman Michael Blitzer, increase their PIPE investments by $15.25 million, bringing the total PIPE funded to over $40 million for the proposed transaction WHEAT RIDGE, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) --  USA Rare Earth, LLC ("USARE" or the "Company") and Inflection Point Acquisition Corp. II (NASDAQ:IPXX) ("IPXX") today announced an additional $15.25 million of PIPE funding received from affiliates of IPXX and other related investors, incl ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Madison Square Garden Sports Corp. (NYSE: MSGS) today reported financial results for the fiscal second quarter ended December 31, 2024. During the fiscal 2025 second quarter, the New York Knicks ("Knicks") and New York Rangers ("Rangers") began their 2024-25 regular seasons, playing a combined three more games at the Madison Square Garden Arena ("The Garden") as compared to the prior year quarter. In addition to the positive impact of those additional home games, the C ...

- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck's KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 monotherapy trial expanded to include cohorts in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Ongoing commitment to innovative cancer therapies for patients with limited treatment options BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp ...

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET.   A webcast of Sensei's presentation will be available in the Investors ...

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 04, 2025 7:27 AM EST | Source: Cardiol Therapeutics Inc.Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that ...

Rise in theadoption of Industry 4.0 to enable real-time processing of data and reduce latency and adoption of cloud computing to enable scalability, flexibility, and cost-effectiveness of hybrid cloud solutions are also anticipated to create lucrative opportunities for market growth.Wilmington, New Castle, Delaware , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Hybrid Cloud Market by Component (Solution and Services), Service Model (Software as a Service (SaaS), Infr ...

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan's ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a hea ...